Judge Orders ImClone's Scientists Off Patent
Scientists at biopharmaceutical company ImClone Systems Inc. copied the work of three Israeli researchers before securing a patent for the firm's top-selling cancer drug, according to a federal judge's highly anticipated...To view the full article, register now.
Already a subscriber? Click here to view full article